专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07659416B2 Monomolecular conductive complex, conductive self-assembled film and assembly of electrode composed of metal and semiconductor making use of the same 失效
标题翻译：单分子导电复合物，导电自组装膜和由金属和半导体组成的电极组合使用相同
公开(公告)号：US07659416B2
公开(公告)日：2010-02-09
申请号：US11886725
申请日：2006-03-17
申请人： Masamichi Fujihira , Fumie Sato , Yuuki Takayama , Go Ono
发明人： Masamichi Fujihira , Fumie Sato , Yuuki Takayama , Go Ono
IPC分类号： C07F1/00 , C07F3/00 , C07F15/00 , C07C327/00 , C07C395/00
CPC分类号： H01B1/125 , C07C327/22 , C07F7/0805
摘要： Enediyne compounds of the formula: (1) characterized in that the structure thereof is very simple and the production process is easy, and that the molecular length thereof is shorter than those of compounds having been proposed. Consequently, electrode assemblies comprising any of these enediyne compounds are highly promising in the application to nanomolecular wiring (nanomolecular wire) whose production has been difficult.
摘要翻译：具有下式的恩二炔化合物：（1）其特征在于其结构非常简单，制备方法容易，其分子长度短于已提出的化合物的分子长度。因此，包含任何这些烯化合物的电极组件在其难以生产的纳米分子布线（纳米分子线）的应用中是非常有希望的。

2. 发明申请

US20060270740A1 Prostaglandin derivatives 审中-公开
标题翻译：前列腺素衍生物
公开(公告)号：US20060270740A1
公开(公告)日：2006-11-30
申请号：US10545785
申请日：2004-02-19
申请人： Fumie Sato , Tohru Tanami , Naoya Ono , Makoto Yagi , Takayuki Seki , Mariko Sato
发明人： Fumie Sato , Tohru Tanami , Naoya Ono , Makoto Yagi , Takayuki Seki , Mariko Sato
IPC分类号： A61K31/557
CPC分类号： C07C405/0016
摘要： A prostaglandin derivative represented by the formula (wherein X is a halogen atom; Y is ethylene group, vinylene group or ethylylene group; Z is a group represented by —(CH2)m, —O(CH2)n— or —S(O)p—(CH2)n— (m is an integer of 0 to 3; n is an integer of 0 to 2; and p is an integer of 0 to 2); R1 is a hydrogen atom, a C1-5 alkyl group or a substituted C1-5 alkyl group; R2 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted by C1-4 alkyl group or C4-15 cycloalkylalkyl group; and R3 is a hydrogen atom, a halogen atom or a C1-5 alkyl group or a substituted C1-5 alkyl group), a pharmaceutically acceptable salt thereof or a hydrate thereof which has an excellent antagonism to prostaglandin DP receptor and, therefore, is useful against diseases such as allergic rhinitis, nasal obstruction, asthma, allergic conjunctivitis, systemic mastocytosis and disorder of systemic mast cell activation.
摘要翻译：由式（其中X是卤素原子; Y是亚乙基，亚乙烯基或亚乙基）表示的前列腺素衍生物; Z是由 - （CH 2 CH 2）m表示的基团，（CH 2）n - 或 - （CH 2）n - （CH 2）n - ）n（m为0〜3的整数，n为0〜2的整数，p为0〜2的整数），R 1〜氢原子，C 1-5烷基或取代的C 1-5烷基; R 2是C 1 -C 6烷基， 3-10个环烷基，被C 1-4烷基取代的C 3-10环烷基或C 1-4 - >环烷基烷基; R 3是氢原子，卤素原子或C 1-5烷基或取代的C 1-5 - >烷基），其药学上可接受的盐或其水合物，其对前列腺素DP受体具有优异的拮抗作用，因此可用于治疗过敏性鼻炎，鼻塞离子，哮喘，过敏性结膜炎，全身肥大细胞增多症和系统性肥大细胞活化紊乱。

3. 发明授权

US06455584B1 Prostaglandin E1 derivatives 失效
标题翻译：前列腺素E1衍生物
公开(公告)号：US06455584B1
公开(公告)日：2002-09-24
申请号：US09937782
申请日：2002-01-04
申请人： Fumie Sato , Tohru Tanami , Hideo Tanaka , Naoya Ono , Makoto Yagi , Hitomi Hirano
发明人： Fumie Sato , Tohru Tanami , Hideo Tanaka , Naoya Ono , Makoto Yagi , Hitomi Hirano
IPC分类号： C07C17700
CPC分类号： C07C405/00 , A61K31/5575 , C07C405/0033
摘要： To provide a prostaglandin derivative represented by the formula: wherein A is an ethylene group, a vinylene group, an ethynylene group, O(CH2)q or S(O)r(CH2)q, R1 is a C3-10 cycloalkyl group, a C1-4 alkyl-C3-10 cycloalkyl group, a C3-10 cycloalkyl-C1-4 alkyl group, a C1-10 alkyl group, a C1-10 alkyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s), a C2-10 alkenyl group, a C2-10 alkenyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s), a C2-10 alkynyl group, a C2-10 alkynyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s) or a bridged cyclic hydrocarbon group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, m is an integer of 1 to 5, n is an integer of 1 to 4, p is 0, 1 or 2, q is an integer of 1 to 5 and r is 0, 1 or 2; a pharmaceutically acceptable salt thereof or a hydrate thereof exhibit excellent action in inhibiting the growth of vascular smooth muscle and is useful as a drug for inhibition of restenosis after percutaneous transluminal coronary angioplasty.
摘要翻译：提供由下式表示的前列腺素衍生物：其中A是亚乙基，亚乙烯基，亚乙炔基，O（CH 2）q或S（O）r（CH 2）q，R 1是C 3-10环烷基， C 1-4烷基-C 3-10环烷基，C 3-10环烷基-C 1-4烷基，C 1-10烷基，被羟基或C 1-4烷氧基取代的C 1-10烷基 C2-10链烯基，被羟基或C1-4烷氧基取代的C2-10烯基，C2-10炔基，被羟基取代的C2-10炔基基团或C 1-4烷氧基或桥连环烃基，R 2是氢原子，C 1-10烷基或C 3-10环烷基，m是1至5的整数，n 是1〜4的整数，p为0,1或2，q为1〜5的整数，r为0,1或2。其药学上可接受的盐或其水合物在抑制血管平滑肌的生长中表现出优异的作用，并且可用作用于抑制经皮腔内冠状动脉成形术后再狭窄的药物。

4. 发明授权

US06333441B1 Preparation of cis—olefins 失效
标题翻译：顺式烯烃的制备
公开(公告)号：US06333441B1
公开(公告)日：2001-12-25
申请号：US08026681
申请日：1993-03-04
申请人： Fumie Sato , Katsuaki Miyaji , Takehiro Amano
发明人： Fumie Sato , Katsuaki Miyaji , Takehiro Amano
IPC分类号： C07C505
CPC分类号： C07D309/12 , C07B35/02 , C07B2200/09 , C07C5/09 , C07C29/17 , C07C51/36 , C07C69/007 , C07C2523/44 , C07F7/1892 , C07C33/03
摘要： A cis-olefin of the formula: R1—CH═CH—R2 is prepared by reducing an alkyne of the formula: R1—C≡C—R2 with formic acid in the presence of a palladium catalyst. R1 and R2 are independently selected from the group consisting of a hydrogen atom, ester group, substituted silyl group, carboxyl group, cyano group, aliphatic C1-C20 hydrocarbon group, and phenyl group. The cis-olefin which is a useful intermediate for the synthesis of fine chemicals is selectively produced in high yields.
摘要翻译：通过在钯催化剂存在下用甲酸还原具有下式的R 1 -C = C-R 2的炔来制备下式的顺式烯烃：R1-CH = CH-R2。 R1和R2独立地选自氢原子，酯基，取代的甲硅烷基，羧基，氰基，脂族C1-C20烃基和苯基。作为合成精细化学品的有用中间体的顺式烯烃以高产率选择性地生产。

5. 发明授权

US5545666A Prostaglandin derivatives 失效
标题翻译：前列腺素衍生物
公开(公告)号：US5545666A
公开(公告)日：1996-08-13
申请号：US290745
申请日：1995-04-19
申请人： Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
发明人： Fumie Sato , Takehiro Amano , Kazuya Kameo , Tohru Tanami , Masaru Mutoh , Naoya Ono , Jun Goto
IPC分类号： C07C405/00 , C01C405/00 , A61K31/557
CPC分类号： C07C405/0016
摘要： A prostaglandin derivative represented by formula ##STR1## wherein R.sup.1 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl group, and R.sup.2 represents a cyclohexyl group or a cyclopentylmethyl group. This compound has physiological activities such as platelet aggregation-inhibiting action, renal blood vessel and coronary blood vessel-dilating actions and the like, and is useful for treatment of renal failure and diseases of circulatory organs.
摘要翻译： PCT No.PCT / JP93 / 01493 Sec。 371日期1995年04月19日 102（e）1995年4月19日PCT PCT 1993年10月18日PCT公布。公开号WO94 / 08959 日本1994年4月28日由式表示的前列腺素衍生物，其中R1表示氢原子或C1-C6烷基，R2表示环己基或环戊基甲基。该化合物具有血小板聚集抑制作用，肾血管和冠状血管扩张作用等的生理活性，可用于治疗肾衰竭和循环器官疾病。

6. 发明授权

US4837339A 4-Substituted-1,2,3,6-tetrahydrophthalic acid anhydride 失效
标题翻译： 4-取代的-1,2,3,6-四氢邻苯二甲酸酐
公开(公告)号：US4837339A
公开(公告)日：1989-06-06
申请号：US39726
申请日：1987-04-20
申请人： Fumie Sato
发明人： Fumie Sato
IPC分类号： C07F7/08 , C07F7/12 , C07F7/18 , C08G59/40 , C08G59/42 , C08K5/54 , C08K5/5419 , C08K5/5425
CPC分类号： C08K5/54 , C07F7/12 , C07F7/1836
摘要： A novel 4-substituted-1,2,3,6-tetrahydrophthalic acid anhydride represented by the structural formula [I]: ##STR1## where R.sup.1 represents a lower alkoxy group, and R.sup.2 and R.sup.3 each represents a lower alkyl group or a lower alkoxy group, said 4-substituted-1,2,3,6-tetrahydrophthalic acid anhydride being liquid. The novel compound is useful as coupling agents, plasticizers, curing agents, etc.
摘要翻译：由结构式[I]表示的新型4-取代-1,2,3,6-四氢邻苯二甲酸酐：其中R 1表示低级烷氧基，R 2和R 3各自表示低级烷基或低级烷氧基，所述4-取代-1,2,3,6-四氢邻苯二甲酸酐为液体。该化合物可用作偶联剂，增塑剂，固化剂等。

7. 发明申请

US20040167344A1 Process for producing organotitanium compound and process for addition reaction 失效
标题翻译：生产有机钛化合物的方法和加成反应方法
公开(公告)号：US20040167344A1
公开(公告)日：2004-08-26
申请号：US10786150
申请日：2004-02-26
申请人： Fumie Sato , Nissan Chemical Industries, Ltd.
发明人： Fumie Sato
IPC分类号： C07F007/28
CPC分类号： C07F7/28 , C07F7/083
摘要： A process for producing an organotitanium compound capable of regioselectively converting a substituted acetylene compound into polysubstituted benzene or polysubstituted pyridine. The process comprises reacting an acetylene compound represented by the formula (1) 1 nullwhere R1 and R2 denote a C1-20 alkyl group or the likenull in the presence of a prescribed titanium compound and a Grignard reagent with a compound represented by the formula (4) 2 nullwhere R3 and R4 denote a hydrogen atom or the likenull and further reacting with a compound represented by the formula (5) 3 nullwhere R5 denotes a hydrogen atom or the like, Z denotes CRnull (where Rnull denotes a hydrogen atom or the like), nitrogen atom, X6 denotes a halogen atom or the like, and m is 0 or 1nullthereby giving the titanium compound represented by the formula (6) and/or (7). 4 nullwhere R1nullR5, Z, X6, and m are defined as above; and Xp and Xq denote any of X1nullX4null.
摘要翻译：一种制备能够将取代的乙炔化合物区域选择性转化为多取代的苯或多取代的吡啶的有机钛化合物的方法。该方法包括在规定的钛化合物和格氏试剂的存在下，使由式（1）表示的乙炔化合物[其中R 1和R 2表示C 1-20烷基等] 由式（4）表示的化合物[其中R 3和R 4表示氢原子等]，并进一步与式（5）表示的化合物反应[其中R 5表示氢原子等等，Z表示CR'（其中R'表示氢原子等），氮原子，X 6表示卤素原子等，m表示0或1，由此得到由式（6）和/或（7）。 [其中R 1〜R 5，Z，X 6和m如上所定义; X和p均表示X 1〜X 4中的任一个。

8. 发明授权

US06613932B1 Prostaglandin derivatives 失效
标题翻译：前列腺素衍生物
公开(公告)号：US06613932B1
公开(公告)日：2003-09-02
申请号：US10070752
申请日：2002-03-11
申请人： Fumie Sato , Tohru Tanami , Hideo Tanaka , Naoya Ono , Makoto Yagi , Hitomi Hirano
发明人： Fumie Sato , Tohru Tanami , Hideo Tanaka , Naoya Ono , Makoto Yagi , Hitomi Hirano
IPC分类号： C07C6974
CPC分类号： C07C405/00
摘要： A prostaglandin derivative represented by the formula: [wherein X is CH2, O or S(O)q1, Y is an ethylene group, a vinylene group, an ethynylene group, O(CH2)t1 or S(O)q2(CH2)t1, Z is an ethylene group, a vinylene group or an ethynylene group, R1 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, R2 is a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group, a C3-10 cycloalkyl group, a C1-5 alkyl-C3-10 cycloalkyl group, a C3-10 cycloalkyl-C1-5 alkyl group, a hydroxy-C1-5 alkyl group, a halogeno-C1-5 alkyl group, a C1-5 alkoxy-C1-5 alkyl group, a C2-4 alkoxycarbonyl-C1-5 alkyl group, a carboxyl-C1-5 alkyl group, a cyano-C1-5 alkyl group, a C1-5 alkyl group substituted with a group represented by the formula: —NR7R8, an acyl group, a group represented by the formula: —(CH2)t2CH(NH2)COOR9, etc., and R3 is a hydrogen atom, a C1-10 alkyl group, etc.], a pharmaceutically acceptable salt thereof or a hydrate thereof. Novel prostaglandin derivatives of the present invention have an excellent action in inhibiting the growth of vascular smooth muscle, and are useful as drugs for prevention or treatment of the restenosis after PTCA, etc.
摘要翻译：由下式表示的前列腺素衍生物[其中X为CH 2，O或S（O）q1，Y为亚乙基，亚乙烯基，亚乙炔基，O（CH 2）t 1或S（O）q 2（CH 2） t1，Z是亚乙基，亚乙烯基或亚乙炔基，R1是氢原子，C1-10烷基或C3-10环烷基，R2是C1-10烷基，C2-10烯基基团，C 2-10炔基，C 3-10环烷基，C 1-5烷基-C 3-10环烷基，C 3-10环烷基-C 1-5烷基，羟基-C 1-5烷基，卤代C 1-5烷基，C 1-5烷氧基-C 1-5烷基，C 2-4烷氧基羰基-C 1-5烷基，羧基-C 1-5烷基，氰基-C 1-5烷基，由下式表示的C1-5烷基：-NR7R8，酰基，由下式表示的基团： - （CH2）t2CH（NH2）COOR9等，R3为氢原子， C 1-10烷基等]，其药学上可接受的盐或其水合物。本发明的新型前列腺素衍生物在抑制血管平滑肌生长中具有优异的作用，可用作预防或治疗PTCA等后再狭窄的药物。

9. 发明授权

US06482990B1 Prostaglandin E analogues 失效
标题翻译：前列腺素E类似物
公开(公告)号：US06482990B1
公开(公告)日：2002-11-19
申请号：US10070154
申请日：2002-03-04
申请人： Fumie Sato , Tohru Tanami , Hideo Tanaka , Naoya Ono , Makoto Yagi
发明人： Fumie Sato , Tohru Tanami , Hideo Tanaka , Naoya Ono , Makoto Yagi
IPC分类号： C07L40500
CPC分类号： C07C405/00 , C07C405/0025
摘要： A prostaglandin analog represented by Formula (I): [wherein A is an ethylene group, a vinylene group or an ethynylene group, Y1 and Y2 are the same or different, and each a hydrogen atom, a halogen atom, a cyano group, —CONR3R4 (wherein R3 and R4 are the same or different, and each a hydrogen atom or a C1-6 alkyl group, or R3 and R4 together with the nitrogen atom to which they are attached form a C4-8 cyclic amine), a C1-3 aminoalkyl group, a C1-6 hydroxyalkyl group, NR5R6 (wherein R5 and R6 are the same or different, and each a hydrogen atom or a C1-6 alkyl group), a hydroxyl group, a C1-6 alkoxy group, a C1-9 alkyl group, a C1-6 alkyl group substituted with halogen(s), a C1-5 acyl group or COOR7 (wherein R7 is a hydrogen atom, a C1-6 alkyl group or a phenyl group), R1 and R2 are the same or different, and each a hydrogen atom, a halogen atom, a C1-9 alkyl group or a C1-6 alkyl group substituted with halogen(s), m is an integer of 0 to 6, and n is an integer of 0 to 3], a pharmaceutically acceptable salt thereof or a hydrate thereof.
摘要翻译：由式（I）表示的前列腺素类似物：[其中A是亚乙基，亚乙烯基或亚乙炔基，Y1和Y2相同或不同，氢原子，卤素原子，氰基 - CONR 3 R 4（其中R 3和R 4相同或不同，并且各自为氢原子或C 1-6烷基，或者R 3和R 4与它们所连接的氮原子一起形成C 4-8环胺），C 1 -3氨基烷基，C1-6羟基烷基，NR5R6（其中R5和R6相同或不同，各自为氢原子或C1-6烷基），羟基，C1-6烷氧基， C1-9烷基，被卤素取代的C1-6烷基，C1-5酰基或COOR7（其中R7是氢原子，C1-6烷基或苯基），R1和R2 各自为氢原子，卤素原子，C1-9烷基或被卤素取代的C1-6烷基，m为0〜6的整数，n为整数 0〜3]，药物其可接受的盐或其水合物。

10. 发明授权

US06329539B1 Prostagladin derivatives 有权
标题翻译：前列腺素衍生物
公开(公告)号：US06329539B1
公开(公告)日：2001-12-11
申请号：US09701187
申请日：2000-11-27
申请人： Fumie Sato , Tohru Tanami , Kazuya Kameo , Kenji Yamada , Shigeru Okuyama , Naoya Ono
发明人： Fumie Sato , Tohru Tanami , Kazuya Kameo , Kenji Yamada , Shigeru Okuyama , Naoya Ono
IPC分类号： C07C5900
CPC分类号： A61K31/5575 , A61K31/557 , C07C405/00 , Y10S514/923
摘要： A prostaglandin derivative represented by the formula: wherein X is a halogen atom, n is an integer of 1 to 5, R1 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with C1-4 alkyl group(s), a C4-13 cycloalkylalkyl group, a C5-10 alkyl group, a C5-10 alkenyl group, a C5-10 alkynyl group or a bridged cyclic hydrocarbon group, and R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, or a pharmaceutically acceptable salt thereof.
摘要翻译：由下式表示的前列腺素衍生物：其中X为卤素原子，n为1〜5的整数，R1为C3-10环烷基，被C1-4烷基取代的C3-10环烷基， C 5-10烷基，C5-10烯基，C5-10炔基或桥连环烃基，R2是氢原子，C1-10烷基或C3 -10环烷基，或其药学上可接受的盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式